Effect of intravenous iron supplementation on hepatic cytochrome P450 3A4 activity in hemodialysis patients: A prospective, open-label study

Clinical Therapeutics

Volumn 29, Issue 12, 2007, Pages 2699-2705

  Pai, Amy Barton ^a,b   Norenberg, Jeffrey ^a   Boyd, Alex ^a   Raj, Dominic ^b   Chan, Lingtak Neander ^c  

^a UNIVERSITY OF NEW MEXICO   (United States)

^b UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

drug metabolism; hemodialysis; iron; pharmacokinetics

Indexed keywords

CYTOCHROME P450 3A4; ERYTHROMYCIN; FERRIC HYDROXIDE SUCROSE; FERRITIN; LIVER ENZYME; TRANSFERRIN;

ADULT; ARTICLE; BREATH ANALYSIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMETHYLATION; ENZYME ACTIVITY; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; IRON DEFICIENCY; IRON THERAPY; MALE; OPEN STUDY;

BREATH TESTS; CYTOCHROME P-450 ENZYME SYSTEM; ERYTHROMYCIN; FEMALE; FERRIC COMPOUNDS; HEMATINICS; HUMANS; INFUSIONS, INTRAVENOUS; IRON; LIVER; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL DIALYSIS; SUCROSE;

EID: 38049082546     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2007.12.024     Document Type: Article

References (21)

1. de Wildt S., Kearns G., Leeder J., and van den Anker J. Cytochrome P450 3A: Ontogeny and drug disposition. Clin Pharmacokinet 37 (1999) 485-505
2. Thorn M., Finnstrom N., Lundgren S., et al. Cytochromes P450 and MDR1 mRNA expression along the human gastrointestinal tract. Br J Clin Pharmacol 60 (2005) 54-60
3. Dresser G., Spence J., and Bailey D. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 38 (2000) 41-57
4. Dhur A., Galan P., and Hercberg S. Effects of different degrees of iron deficiency on cytochrome P450 complex and pentose phosphate pathway dehydrogenases in the rat. J Nutr 119 (1989) 40-47
5. Johnston S., Murray K., Martin S., et al. Iron deficiency enhances cholesterol gallstone formation. Surgery 122 (1997) 354-362
6. Arce D., and Keen C. Effects of marginal and severe iron deficiency on hepatic proteins in developing rats are reversible with dietary iron repletion. Reprod Toxicol 7 (1993) 61-72
7. Drueke T. Hyporesponsiveness to recombinant human erythropoietin. Nephrol Dial Transplant 16 Suppl7 (2001) 25-28
8. Gorski J., Hall S., Becker P., et al. In vivo effects of interleukin-10 on human cytochrome P450 activity. Clin Pharmacol Ther 67 (2000) 32-43
9. Rivory L., Slaviero K., and Clarke S. Hepatic cytochrome P450 3A drug metabolism is reduced in cancer patients who have an acute-phase response. Br J Cancer 87 (2002) 277-280
10. Turgeon D., Leichtman A., Lown K., et al. P450 3A activity and cyclosporine dosing in kidney and heart transplant recipients. Clin Pharmacol Ther 56 (1994) 253-260
11. Erythromycin breath test (2004), Metabolic Solutions Inc, Nashua, NH [product information]
12. Streetman D., Bertino Jr. J., and Nafziger A. Phenotyping of drug-metabolizing enzymes in adults: A review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics 10 (2000) 187-216
13. Dowling T., Briglia A., Fink J., et al. Characterization of hepatic cytochrome P4503 A activity in patients with end-stage renal disease. Clin Pharmacol Ther 73 (2003) 427-434
14. Nolin T., Appiah K., Kendrick S., et al. Hemodialysis acutely improves hepatic CYP3A4 metabolic activity. J Am Soc Nephrol 17 (2006) 2363-2367
15. Himmelfarb J. Iron regulation. J Am Soc Nephrol 18 (2007) 379-381
16. Himmelfarb J. Relevance of oxidative pathways in the pathophysiology of chronic kidney disease. Cardiol Clin 23 (2005) 319-330
17. Ganz T. Molecular control of iron transport. J Am Soc Nephrol 18 (2007) 394-400
18. Morgan E. Regulation of cytochromes P450 during inflammation and infection. Drug Metab Rev 29 (1997) 1129-1188
19. Charles K., Rivory L., Brown S., et al. Transcriptional repression of hepatic cytochrome P450 3A4 gene in the presence of cancer. Clin Cancer Res 12 (2006) 7492-7497
20. Kooistra M., Niemantsverdriet E., van Es A., et al. Iron absorption in erythropoietin-treated haemodialysis patients: Effects of iron availability, inflammation and aluminium. Nephrol Dial Transplant 13 (1998) 82-88
21. Sica D., and Gehr T. Calcium-channel blockers and end-stage renal disease: Pharmacokinetic and pharmacodynamic considerations. Curr Opin Nephrol Hypertens 12 (2003) 123-131